ASCO 2020 June Newsmakers
Kathleen Cooney, MD, on Prostate Cancer and Familial and Hereditary Cancer Syndromes:
Researchers urge obtaining family history of all types of cancers plus counseling for men who appear at increased risk of prostate cancer (Medpage Today/ASCO Reading Room)
Selinexor could be new ‘backbone’ in myeloma treatment (Healio)
Features Cristina Gasparetto, MD
Selinexor combination ‘extremely effective’ in relapsed, refractory myeloma (Healio)
Features Cristina Gasparetto, MD
PDIGREE: An adaptive phase III trial of PD-inhibitor Nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI Cabozantinib (CABO) in Metastatic Untreated RCC (Alliance A031704)
Features Tian Zhang, MD
WATCH: The potential of selinexor combinations for RRMM (Multiple Myeloma Hub)
Features Cristina Gasparetto, MD
Thirty Percent of Patients With NSCLC Who Had Actionable Variants Were Not Prescribed Targeted Therapies: Study (Cancer Therapy Advisor)
Features Vishal Vashistha, MD
A Lung Cancer Gamechanger And A Surprise Public Offering: Five Big Moments From ASCO’s First Virtual Conference (Forbes)
Features Tian Zhang, MD
AML Patients Benefit From Palliative Care (Patient Power)
Features Thomas LeBlanc, MD
ASCO 2020 May/June Published Papers
*Duke authors are bolded
Reply to J. Schildmann et al . Journal of Clinical Oncology. Areej El-Jawahri, MD, Thomas W. LeBlanc, MD, and Stephanie J. Lee, MD, MPH
De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer. Journal of Clinical Oncology. May 22, 2020.
E. Shelley Hwang, MD, MPH and Lawrence Solin, MD
June Newsmakers
TOUCHED BY LYME: Community grieves loss of Dr. Neil Spector (LymeDisease.org)
Op-Ed: My patients are in the hospital, yet so alone. How isolation is complicating care during the pandemic (Los Angeles Times)
Features Nathan Gray, MD
Financial toxicity a lingering, often unexpected burden for cancer survivors (Healio)
Features Yousuf Zafar, MD, MHS
Society for Immunotherapy of Cancer Announces Recipients of 2020 Postdoctoral Cancer Immunotherapy Fellowships and Award (SITC)
Features Jacob Kaufman, MD, PhD
Extraordinary Stories - Duke University (Oncology Nursing Foundation)
Features DUMC outpatient Adult Blood and Marrow Transplant Team
Sequencing Options Expand for Patients With HER2+ MBC and Brain Metastases (OncLive)
Carey K. Anders, MD and Sarah L. Sammons, MD
Nine specialty areas at Duke Children's Hospital rank in the top 50 by U.S. News (Duke Dept. of Pediatrics/ USN&WR)
Efficacy of osimertinib against EGFRvIII+ glioblastoma (OncoTarget press release)
Features Madan Kwatra, MD
LISTEN: Breast Cancer and Race: Disparities and Mental Health Effects (breastcancer.org)
Features Lola Fayanju, MD
Mammography Cuts Risk for Fatal Breast Cancers: New Data (Medscape)
Features Jay Baker, MD, FACR, FSBI
American Association of Physicians Selects 3 Indian Americans as 2020 Members (India West)
Features Svati Shah, MD, MHS
American Association for Cancer Research Announces Distinguished Public Service Award Recipients (AACR)
Patricia Spears, MS
Practical Strategies for Treatment of Clear Cell Renal Cell Carcinoma (OncLive)
Features Tian Zhang, MD
Papers
*Duke authors are bolded
PD-1 inhibitors: Do they have a future in the treatment of glioblastoma? Clinical Cancer Research. June 11, 2020.
Mustafa Khasraw, David A. Reardon, Michael Weller and John H. Sampson
Do Histopathology and Clinical Outcomes of Breast Atypia Vary by Race/Ethnicity? Journal of Surgical Research. June 8, 2020. Amanda R. Sergesketter, MD, Samantha M.Thomas, MS, Edgardo R. Parrilla Castellar, MD, PhD, Oluwadamilola M.Fayanju, MD, MA, MPHS, Carolyn Menendez, MD, E. Shelley Hwang, MD, MPH, Jennifer K.Plichta, MD, MS.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. NEJM. June 4, 2020. Neal D. Shore, M.D., Fred Saad, M.D., Michael S. Cookson, M.D., M.M.H.C., Daniel J. George, M.D., Daniel R. Saltzstein, M.D., Ronald Tutrone, M.D., Hideyuki Akaza, M.D., Alberto Bossi, M.D., David F. van Veenhuyzen, M.B., Ch.B., M.Pharm.Med., Bryan Selby, M.S., Xiaolin Fan, Ph.D., Vicky Kang, M.D., Jackie Walling, M.B., Ch.B., Ph.D., and Bertrand Tombal, M.D., Ph.D. for the HERO Study Investigators*
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma (This paper was presented in abstract form as a poster at the American Society for Clinical Oncology meeting, 2017) Gynecologic Oncology. June 2020.
L.R. Duskaa,G.R. Petronib, N. Varhegyib, J. Brownc, D. Jelovacd, K.N. Mooree, W.P. McGuiref, C. Darusg, L.M. Barroilheth, A.A. Secord.
House Calls for Stem Cell Transplants During the COVID-19 Pandemic. Blood. June 2, 2020. Anthony D Sung, Krista R. Nichols, Nelson J. Chao.
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy. JNCCN. June 2020. Eric J. Roeland MD, Kathryn J. Ruddy, MD, Thomas W. LeBlanc, MD, Ryan D. Nipp, MD, Gary Binder, MBA, Silvia Sebastiani, PhD, Ravi Potluri, PGDM, Luke Schmerold, BS, Eros Papademetriou, MA, Lee Schwartzberg, MD, and Rudolph M. Navari, MD.
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019 Journal of Clinical Oncology. June 9, 2020. Veda N. Giri, MD; Karen E. Knudsen, MBA, PhD; William K. Kelly, DO; Heather H. Cheng, MD, PhD; Kathleen A. Cooney, MD; Michael S. Cookson, MD; William Dahut, MD; Scott Weissman, MS; Howard R. Soule, PhD; Daniel P. Petrylak, MD; Adam P. Dicker, MD, PhD; Saud H. AlDubayan, MD; Amanda E. Toland, PhD; Colin C. Pritchard, MD, PhD; Curtis A. Pettaway, MD; Mary B. Daly, MD, PhD; James L. Mohler, MD; J. Kellogg Parsons, MD; Peter R. Carroll, MD, MPH; Robert Pilarski, MS, MSW; Amie Blanco, MS; Ashley Woodson, MS; Alanna Rahm, PhD; Mary-Ellen Taplin, MD; Thomas J. Polascik, MD; Brian T. Helfand, MD, PhD; Colette Hyatt, MS; Alicia K. Morgans, MD, MPH; Felix Feng, MD; Michael Mullane, MD; Jacqueline Powers, MS; Raoul Concepcion, MD; Daniel W. Lin, MD; Richard Wender, MD; James Ryan Mark, MD; Anthony Costello, MBBS; Arthur L. Burnett, MD, MBA; Oliver Sartor, MD35; William B. Isaacs, PhD36; Jianfeng Xu, MD, DrPH24; Jeffrey Weitzel, MD37; Gerald L. Andriole, MD; Himisha Beltran, MD; Alberto Briganti, MD, PhD; Lyndsey Byrne, MS; Anne Calvaresi, DNP; Thenappan Chandrasekar, MD; David Y. T. Chen, MD; Robert B. Den, MD; Albert Dobi, PhD; E. David Crawford, MD; James Eastham, MD; Scott Eggener, MD; Matthew L. Freedman, MD; Marc Garnick, MD; Partrick T. Gomella, MD, MPH; Nathan Handley, MD, MBA; Mark D. Hurwitz, MD; Joseph Izes, MD, MS; R. Jeffrey Karnes, MD; Costas Lallas, MD; Lucia Languino, PhD; Stacy Loeb, MD, MSc; Ana Maria Lopez, MD, MPH; Kevin R. Loughlin, MD, MBA; Grace Lu-Yao, PhD, MPH; S. Bruce Malkowicz, MD; Mark Mann, MD; Patrick Mille, M; Martin M. Miner, MD; Todd Morgan, MD; Jose Moreno, MD; Lorelei Mucci, ScD, MPH; Ronald E. Myers, DSW, PhD; Sarah M. Nielsen, MS; Brock O’Neil, MD; Wayne Pinover, DO; Peter Pinto, MD; Wendy Poage, MHA; Ganesh V. Raj, MD, PhD; Timothy R. Rebbeck, PhD; Charles Ryan, MD; Howard Sandler, MD, MS; Matthew Schiewer, PhD; E. Michael D. Scott, BSc; Brittany Szymaniak, PhD, MS; William Tester, MD1; Edouard J. Trabulsi, MD; Neha Vapiwala, MD; Evan Y. Yu, MD; Charnita Zeigler-Johnson, PhD, MPH; and Leonard G. Gomella, MD.
Efficacy of osimertinib against EGFRvIII+ glioblastoma OncoTarget. June 2, 2020. Gustavo Chagoya, Shawn G. Kwatra, Cory W. Nanni, Callie M. Roberts, Samantha M. Phillips, Sarah Nullmeyergh, Samuel P. Gilmore, Ivan Spasojevic, David L. Corcoran, Christopher C. Young, Karla V. Ballman, Rohan Ramakrishna, Darren A. Cross, James M. Markert, Michael Lim, Mark R. Gilbert, Glenn J. Lesser, and Madan M. Kwatra.
Polymer-assisted intratumoral delivery of ethanol: Preclinical investigation of safety and efficacy in a murine breast cancer model Cold Spring Harbor Laboratory. May 29, 2020. Corrine A. Nief, Robert Morhard, Erika Chelales, Daniel Adrianzen Alvarez, Ioanna Bourla, Christopher T. Lam, Alan A. Sag, View Brian T. Crouch, Jenna L. Mueller, David Katz, Mark W. Dewhirst, Jeffrey I. Everitt, Nirmala Ramanujam.
Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies Clinical Lung Cancer. April 15, 2020. Erica Shen, Joanne Xiu, Rex Bentley, Giselle Y. López, Kyle M. Walsh.